|1.||DeJesus, Edwin: 7 articles (06/2015 - 03/2011)|
|2.||Szwarcberg, Javier: 7 articles (03/2014 - 06/2012)|
|3.||Cheng, Andrew K: 6 articles (06/2015 - 06/2012)|
|4.||Liu, Hui C: 5 articles (08/2015 - 03/2011)|
|5.||Gathe, Joseph: 5 articles (08/2015 - 06/2012)|
|6.||De Clercq, Erik: 5 articles (11/2013 - 01/2008)|
|7.||Mills, Anthony: 4 articles (08/2015 - 06/2012)|
|8.||Plummer, Andrew: 4 articles (06/2015 - 04/2013)|
|9.||Sax, Paul E: 4 articles (06/2015 - 06/2012)|
|10.||White, Kirsten: 4 articles (07/2014 - 06/2012)|
04/01/2014 - "Elvitegravir: a review of its use in adults with HIV-1 infection."
08/01/2013 - "A randomized phase 3 study comparing once-daily elvitegravir with twice-daily raltegravir in treatment-experienced subjects with HIV-1 infection: 96-week results."
05/01/2015 - "Rectal secretions collected at 24 h from treated macaques blocked infection of TZM-bl cells by 50% at dilutions of 1/1000 (raltegravir), 1/800 (dolutegravir) and >1/30 000 (elvitegravir). "
12/01/2013 - "During the last years, raltegravir, elvitegravir and dolutegravir have been proven and established in the antiretroviral treatment of HIV-1 infections as effective, safe and well-tolerated agents. "
12/01/2013 - "In contrast to raltegravir and elvitegravir, dolutegravir shows a high genetic barrier to resistance, and is also applicable for the treatment of several HIV-1 infections with raltegravir and elvitegravir-resistant HIV variants. "
|3.||HIV Infections (HIV Infection)
03/01/2014 - "Elvitegravir for the treatment of HIV infection."
12/01/2012 - "Cobicistat-boosted elvitegravir-based fixed-dose combination antiretroviral therapy for HIV infection."
02/01/2009 - "Elvitegravir, an oral HIV integrase inhibitor, for the potential treatment of HIV infection."
03/01/2015 - "Dolutegravir is the integrase inhibitor of choice for rescue therapy in multiresistant HIV infection, both in integrase inhibitor-naïve patients and in those previously treated with raltegravir or elvitegravir. "
10/01/2014 - "Raltegravir, elvitegravir and dolutegravir are the three Food and Drug Administration (FDA) approved integrase strand transfer inhibitors for clinical treatment of HIV infection. "
|4.||Human Influenza (Influenza)
11/15/2013 - "In this second part of "Dancing with antivirals as chemical formulae" I will focus on a number of chemical compounds that in the last few years have elicited more than common attraction from a commercial viewpoint: (i) favipiravir (T-705), as it is active against influenza, but also several other RNA viruses; (ii) neuraminidase inhibitors such as zanamivir and oseltamivir; (iii) peramivir and laninamivir octanoate, which might be effective against influenza virus following a single (intravenous or inhalation) administration; (iv) sofosbuvir, the (anticipated) cornerstone for the interferon-free therapy of HCV infections; (v) combinations of DAAs (direct antiviral agents) to achieve, in no time, a sustained virus response (SVR) against HCV infection; (vi) HIV protease inhibitors, the latest and most promising being darunavir; (vii) the integrase inhibitors (INIs) (raltegravir, elvitegravir, dolutegravir), representing a new dimension in the anti-HIV armamentarium; (viii), a new class of helicase primase inhibitors (HPIs) that may exceed acyclovir and the other anti-herpes compounds in both potency and safety; (ix) CMX-001, as the latest of Dr. Antonín Holý's legacy for its activity against poxviruses and CMV infections, and (x) noroviruses for which the ideal antiviral compounds are still awaited for. "
09/01/2008 - "Foremost among the newly described antiviral agents that may be developed into drugs are, for the treatment of human papilloma virus (HPV) infections, cPrPMEDAP; for the treatment of herpes simplex virus (HSV) infections, BAY 57-1293; for the treatment of varicella-zoster virus (VZV) infections, FV-100 (prodrug of Cf 1743); for the treatment of cytomegalovirus (CMV) infections, maribavir; for the treatment of poxvirus infections, ST-246; for the treatment of hepatitis B virus (HBV) infections, tenofovir disoproxil fumarate (TDF) (which in the meantime has already been approved in the EU); for the treatment of various DNA virus infections, the hexadecyloxypropyl (HDP) and octadecyloxyethyl (ODE) prodrugs of cidofovir; for the treatment of orthomyxovirus infections (i.e., influenza), peramivir; for the treatment of hepacivirus infections (i.e., hepatitis C), the protease inhibitors telaprevir and boceprevir, the nucleoside RNA replicase inhibitors (NRRIs) PSI-6130 and R1479, and various non-nucleoside RNA replicase inhibitors (NNRRIs); for the treatment of human immunodeficiency virus (HIV) infections, integrase inhibitors (INIs) such as elvitegravir, nucleoside reverse transcriptase inhibitors (NRTIs) such as apricitabine, non-nucleoside reverse transcriptase inhibitors (NNRTIs) such as rilpivirine and dapivirine; and for the treatment of both HCV and HIV infections, cyclosporin A derivatives such as the non-immunosuppressive Debio-025."
|4.||tenofovir disoproxil (Viread)
|7.||Protease Inhibitors (Protease Inhibitor)
|8.||Antiviral Agents (Antivirals)